Although these results demonstrate that tumor-specific genetic depletion of USP8 could significantly enhance the therapeutic efficacy of PD-L1 blockade, the systemically using USP8 inhibitor treatment may also affect the function of other cells including immune cells in vivo. This evidence concerns the gene CD274 and neoplasm.